About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Farallon presses Astellas to cut costs and overhaul drugs research in latest shareholder campaign gripping Tokyo ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Mitsubishi Chemical Group Corp. (MCG; Tokyo) announced that it has decided to transfer its consolidated subsidiary Mitsubishi Tanabe Pharma Corp. (MTPC; ...

Bain's latest acquisition follows a string of hefty investments the private equity firm has made in Japan in recent months.

Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...

Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...

Dubai Bain Capital is in the final stages of negotiations to acquire Mitsubishi Chemical Group's pharmaceutical subs ...

Bain Capital said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare ...

Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity ...